Augustus John Rush

List of Publications by Year
in descending order

641 papers	75,314 citations	511 128 h-index	718 252 g-index
650 all docs	650 docs citations	650 times ranked	37149 citing authors

#	Article	IF	Citations
1	The Epidemiology of Major Depressive Disorder. JAMA - Journal of the American Medical Association, 2003, 289, 3095.	7.4	6,692
2	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1905-1917.	7.2	4,241
3	Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice. American Journal of Psychiatry, 2006, 163, 28-40.	7.2	3,206
4	The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry, 2003, 54, 573-583.	1.3	2,981
5	A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression. New England Journal of Medicine, 2000, 342, 1462-1470.	27.0	1,188
6	Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression. New England Journal of Medicine, 2006, 354, 1231-1242.	27.0	934
7	Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Contemporary Clinical Trials, 2004, 25, 119-142.	1.9	898
8	Medication Augmentation after the Failure of SSRIs for Depression. New England Journal of Medicine, 2006, 354, 1243-1252.	27.0	897
9	Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients. Cognitive Therapy and Research, 1977, 1, 17-37.	1.9	842
10	The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychological Medicine, 2004, 34, 73-82.	4.5	822
11	The inventory for depressive symptomatology (IDS): Preliminary findings. Psychiatry Research, 1986, 18, 65-87.	3.3	794
12	Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report. American Journal of Psychiatry, 2008, 165, 342-351.	7.2	741
13	Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14293-14296.	7.1	729
14	Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter studyâ—â—See accompanying Editorial, in this issue.. Biological Psychiatry, 2000, 47, 276-286.	1.3	612
15	Axis I Psychiatric Comorbidity and Its Relationship to Historical Illness Variables in 288 Patients With Bipolar Disorder. American Journal of Psychiatry, 2001, 158, 420-426.	7.2	611
16	Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder. Neuropsychopharmacology, 2006, 31, 1841-1853.	5.4	572
17	The STAR*D project results: A comprehensive review of findings. Current Psychiatry Reports, 2007, 9, 449-459.	4.5	554
18	Vagus Nerve Stimulation for Treatment-Resistant Depression: A Randomized, Controlled Acute Phase Trial. Biological Psychiatry, 2005, 58, 347-354.	1.3	542

#	Article	IF	Citations
19	Remissions in Maternal Depression and Child Psychopathology. JAMA - Journal of the American Medical Association, 2006, 295, 1389.	7.4	539
20	Antidepressant Actions of Histone Deacetylase Inhibitors. Journal of Neuroscience, 2009, 29, 11451-11460.	3.6	535
21	A Comparison of Lithium and T$_3$Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1519-1530.	7.2	526
22	What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression. Psychiatric Services, 2009, 60, 1439-1445.	2.0	508
23	Estimating Individualized Treatment Rules Using Outcome Weighted Learning. Journal of the American Statistical Association, 2012, 107, 1106-1118.	3.1	472
24	Vagus Nerve Stimulation (VNSâ„¢) for Treatment-Resistant Depression Efficacy, Side Effects, and Predictors of Outcome. Neuropsychopharmacology, 2001, 25, 713-728.	5.4	456
25	Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STARâˆ—D) study. Psychiatric Clinics of North America, 2003, 26, 457-494.	1.3	456
26	Implementing Evidence-Based Practices for Persons With Severe Mental Illnesses. Psychiatric Services, 2001, 52, 45-50.	2.0	445
27	The Stanley Foundation Bipolar Treatment Outcome Network. Journal of Affective Disorders, 2001, 67, 45-59.	4.1	436
28	Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant Treatment. American Journal of Human Genetics, 2006, 78, 804-814.	6.2	434
29	Effect of Age at Onset on the Course of Major Depressive Disorder. American Journal of Psychiatry, 2007, 164, 1539-1546.	7.2	393
30	Vagus nerve stimulation: a new tool for brain research and therapyâˆ—. Biological Psychiatry, 2000, 47, 287-295.	1.3	389
31	ECT Remission Rates in Psychotic Versus Nonpsychotic Depressed Patients: A Report from CORE. Journal of ECT, 2001, 17, 244-253.	0.6	384
32	Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychological Medicine, 2010, 40, 41-50.	4.5	366
33	Gender differences in depression: Findings from the STAR*D study. Journal of Affective Disorders, 2005, 87, 141-150.	4.1	359
34	Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychological Medicine, 2004, 34, 1299-1308.	4.5	352
35	Early physical and sexual abuse associated with an adverse course of bipolar illness. Biological Psychiatry, 2002, 51, 288-297.	1.3	350
36	Speed of Response and Remission in Major Depressive Disorder With Acute Electroconvulsive Therapy (ECT). Journal of Clinical Psychiatry, 2004, 65, 485-491.	2.2	346

#	Article	IF	Citations
37	Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study. Biological Psychiatry, 2005, 58, 355-363.	1.3	345
38	An Evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: A Sequenced Treatment Alternatives to Relieve Depression Trial Report. Biological Psychiatry, 2006, 59, 493-501.	1.3	344
39	Treating Major Depression in Primary Care Practice. Archives of General Psychiatry, 1998, 55, 1121.	12.3	341
40	Methods to Improve Diagnostic Accuracy in a Community Mental Health Setting. American Journal of Psychiatry, 2000, 157, 1599-1605.	7.2	338
41	Effect Size of Lithium, Divalproex Sodium, and Carbamazepine in Children and Adolescents With Bipolar Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2000, 39, 713-720.	0.5	332
42	Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. American Journal of Psychiatry, 2011, 168, 689-701.	7.2	329
43	The Inventory of Depressive Symptomatology (IDS): Clinician (IDSâ€C) and Selfâ€Report (IDSâ€SR) ratings of depressive symptoms. International Journal of Methods in Psychiatric Research, 2000, 9, 45-59.	2.1	328
44	Two-Year Outcome of Vagus Nerve Stimulation (VNS) for Treatment of Major Depressive Episodes. Journal of Clinical Psychiatry, 2005, 66, 1097-1104.	2.2	323
45	A One-Year Comparison of Vagus Nerve Stimulation with Treatment as Usual for Treatment-Resistant Depression. Biological Psychiatry, 2005, 58, 364-373.	1.3	319
46	Onset and Persistence of Postpartum Depression in an Inner-City Maternal Health Clinic System. American Journal of Psychiatry, 2001, 158, 1856-1863.	7.2	312
47	Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Research, 2000, 42, 203-210.	1.6	310
48	Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1531-1541.	7.2	300
49	STAR*D: What Have We Learned?. American Journal of Psychiatry, 2007, 164, 201-204.	7.2	300
50	Cognitive patterns in symptomatic and remitted unipolar major depression.. Journal of Abnormal Psychology, 1984, 93, 31-40.	1.9	298
51	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. American Journal of Psychiatry, 2007, 164, 739-752.	7.2	297
52	The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs. Journal of Clinical Psychiatry, 2002, 63, 963-971.	2.2	291
53	Hippocampal Remodeling and Damage by Corticosteroids Implications for Mood Disorders. Neuropsychopharmacology, 1999, 21, 474-484.	5.4	285
54	Clinical Results for Patients With Major Depressive Disorder in theTexas Medication Algorithm Project. Archives of General Psychiatry, 2004, 61, 669.	12.3	284

#	Article	IF	Citations
55	A Genomewide Association Study Points to Multiple Loci That Predict Antidepressant Drug Treatment Outcome in Depression. Archives of General Psychiatry, 2009, 66, 966.	12.3	284
56	Sertraline as a first-line treatment for cholestatic pruritus. Hepatology, 2007, 45, 666-674.	7.3	274
57	The Treatment of Chronic Depression, Part 3. Journal of Clinical Psychiatry, 1998, 59, 608-619.	2.2	266
58	Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biological Psychiatry, 2002, 51, 280-287.	1.3	262
59	Relief of Expressed Suicidal Intent by ECT: A Consortium for Research in ECT Study. American Journal of Psychiatry, 2005, 162, 977-982.	7.2	257
60	The FKBP5-Gene in Depression and Treatment Response—an Association Study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biological Psychiatry, 2008, 63, 1103-1110.	1.3	240
61	Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biological Psychiatry, 2004, 55, 538-545.	1.3	239
62	Randomized, Placebo-Controlled Trial of Mixed Amphetamine Salts for Symptoms of Comorbid ADHD in Pediatric Bipolar Disorder After Mood Stabilization With Divalproex Sodium. American Journal of Psychiatry, 2005, 162, 58-64.	7.2	238
63	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1161-1172.	7.2	233
64	Self-Rated Global Measure of the Frequency, Intensity, and Burden of Side Effects. Journal of Psychiatric Practice, 2006, 12, 71-79.	0.7	227
65	Psychotherapy and Medication in the Treatment of Adult and Geriatric Depression. Journal of Clinical Psychiatry, 2005, 66, 455-468.	2.2	227
66	15 Years of Clinical Experience With Bupropion HCl. Primary Care Companion To the Journal of Clinical Psychiatry, 2005, 7, 106-13.	0.6	225
67	High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biological Psychiatry, 2002, 51, 305-311.	1.3	220
68	GABAB Receptors, Schizophrenia and Sleep Dysfunction. CNS Drugs, 2009, PAP, 627-47.	5.9	220
69	Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies. American Journal of Psychiatry, 2013, 170, 207-217.	7.2	216
70	Comorbid psychiatric disorders in depressed outpatients: Demographic and clinical features. Journal of Affective Disorders, 2005, 87, 43-55.	4.1	210
71	Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study. Comprehensive Psychiatry, 2008, 49, 238-246.	3.1	209
72	Can Phase III Trial Results of Antidepressant Medications Be Generalized to Clinical Practice? A STAR*D Report. American Journal of Psychiatry, 2009, 166, 599-607.	7.2	209

#	Article	IF	Citations
73	Association Between a Functional Serotonin Transporter Promoter Polymorphism and Citalopram Treatment in Adult Outpatients With Major Depression. Archives of General Psychiatry, 2007, 64, 783.	12.3	208
74	Does psychosocial functioning improve independent of depressive symptoms? a comparison of nefazodone, psychotherapy, and their combination. Biological Psychiatry, 2002, 51, 123-133.	1.3	204
75	Genetic Markers of Suicidal Ideation Emerging During Citalopram Treatment of Major Depression. American Journal of Psychiatry, 2007, 164, 1530-1538.	7.2	203
76	Polysomnographic Findings in Recently Drug-Free and Clinically Remitted Depressed Patients. Archives of General Psychiatry, 1986, 43, 878.	12.3	193
77	Association Between Major Depressive Episodes in Patients With Chronic Kidney Disease and Initiation of Dialysis, Hospitalization, or Death. JAMA - Journal of the American Medical Association, 2010, 303, 1946.	7.4	193
78	Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biological Psychiatry, 1998, 44, 3-14.	1.3	192
79	Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. Journal of Affective Disorders, 1999, 55, 149-157.	4.1	192
80	MAOIs in the Contemporary Treatment of Depression. Neuropsychopharmacology, 1995, 12, 185-219.	5.4	190
81	Cross-Disorder Genomewide Analysis of Schizophrenia, Bipolar Disorder, and Depression. American Journal of Psychiatry, 2010, 167, 1254-1263.	7.2	190
82	Association of GRIK4 With Outcome of Antidepressant Treatment in the STAR*D Cohort. American Journal of Psychiatry, 2007, 164, 1181-1188.	7.2	189
83	Prospective, Long-Term, Multicenter Study of the Naturalistic Outcomes of Patients With Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2006, 67, 688-695.	2.2	189
84	The Montgomery Ãsberg and the Hamilton ratings of depression: A comparison of measures. European Neuropsychopharmacology, 2006, 16, 601-611.	0.7	183
85	The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder. Schizophrenia Research, 2008, 100, 60-69.	2.0	179
86	Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illness. Comprehensive Psychiatry, 2003, 44, 263-269.	3.1	175
87	Mixed Hypomania in 908 Patients With Bipolar Disorder Evaluated Prospectively in the Stanley Foundation Bipolar Treatment Network. Archives of General Psychiatry, 2005, 62, 1089.	12.3	175
88	Texas Medication Algorithm Project. Journal of Clinical Psychiatry, 1998, 59, 345-351.	2.2	174
89	The Texas Medication Algorithm Project. Journal of Clinical Psychiatry, 1999, 60, 142-156.	2.2	174
90	Research issues in the study of difficult-to-treat depression. Biological Psychiatry, 2003, 53, 743-753.	1.3	169

#	Article	IF	Citations
91	Children of Depressed Mothers 1 Year After the Initiation of Maternal Treatment: Findings From the STAR*D-Child Study. American Journal of Psychiatry, 2008, 165, 1136-1147.	7.2	169
92	Workplace performance effects from chronic depression and its treatment. Journal of Health Economics, 1998, 17, 511-535.	2.7	167
93	The Influence of Age on the Response of Major Depression to Electroconvulsive Therapy: A C.O.R.E. Report. American Journal of Geriatric Psychiatry, 2001, 9, 382-390.	1.2	167
94	Acupuncture: a promising treatment for depression during pregnancy. Journal of Affective Disorders, 2004, 83, 89-95.	4.1	167
95	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1161.	7.2	167
96	Residual Symptoms in Depressed Outpatients Who Respond by 50% But Do Not Remit to Antidepressant Medication. Journal of Clinical Psychopharmacology, 2011, 31, 180-186.	1.4	166
97	The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia. Journal of Clinical Psychiatry, 2004, 65, 500-508.	2.2	165
98	Clinical and Demographic Features of Atypical Depression in Outpatients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2005, 66, 1002-1011.	2.2	165
99	Sex differences in response to citalopram: A STARâˆ—D report. Journal of Psychiatric Research, 2009, 43, 503-511.	3.1	164
100	International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials, 2011, 12, 4.	1.6	163
101	The Stanley Foundation Bipolar Treatment Outcome Network. Journal of Affective Disorders, 2001, 67, 33-44.	4.1	162
102	Prevalence of Major Depressive Episode in CKD. American Journal of Kidney Diseases, 2009, 54, 424-432.	1.9	162
103	A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Research, 2005, 133, 129-133.	3.3	159
104	The Dexamethasone Suppression Test in Patients With Mood Disorders. Journal of Clinical Psychiatry, 1996, 57, 470-484.	2.2	158
105	Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. Acta Psychiatrica Scandinavica, 2005, 112, 425-433.	4.5	157
106	Fluoxetine Versus Placebo in Preventing Relapse of Major Depression in Children and Adolescents. American Journal of Psychiatry, 2008, 165, 459-467.	7.2	156
107	Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM^{TM}-p) for longitudinal assessment of bipolar illness. Psychological Medicine, 2000, 30, 1391-1397.	4.5	155
108	Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy. JAMA Psychiatry, 2015, 72, 1102.	11.0	155

#	Article	IF	Citations
109	Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology, 2017, 78, 105-113.	2.7	155
110	A Descriptive Analysis of Minor Depression. American Journal of Psychiatry, 2002, 159, 637-643.	7.2	154
111	The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication. Molecular Psychiatry, 2010, 15, 856-867.	7.9	153
112	Selecting Among Second-Step Antidepressant Medication Monotherapies. Archives of General Psychiatry, 2008, 65, 870.	12.3	152
113	Improving the Prediction of Treatment Response in Depression: *Integration of Clinical, Cognitive, Psychophysiological, Neuroimaging, and Genetic Measures*. CNS Spectrums, 2008, 13, 1066-1086.	1.2	150
114	Children of Depressed Mothers 1 Year After Remission of Maternal Depression: Findings From the STAR*D-Child Study. American Journal of Psychiatry, 2011, 168, 593-602.	7.2	149
115	What Clinical and Symptom Features and Comorbid Disorders Characterize Outpatients with Anxious Major Depressive Disorder: A Replication and Extension. Canadian Journal of Psychiatry, 2006, 51, 823-835.	1.9	148
116	Fluoxetine in child and adolescent depression: Acute and maintenance treatment. Depression and Anxiety, 1998, 7, 32-39.	4.1	147
117	Evaluating the Impact of Pharmacists in Mental Health: A Systematic Review. Pharmacotherapy, 2003, 23, 1634-1644.	2.6	145
118	Strengthening clinical effectiveness trials: Equipoise-stratified randomization. Biological Psychiatry, 2001, 50, 792-801.	1.3	144
119	Measurement-Based Care in Psychiatric Practice. Journal of Clinical Psychiatry, 2011, 72, 1136-1143.	2.2	142
120	Slow-wave activity in NREM sleep: sex and age effects in depressed outpatients and healthy controls. Psychiatry Research, 2000, 95, 201-213.	3.3	140
121	Genome-Wide Association Study of Suicide Attempts in Mood Disorder Patients. American Journal of Psychiatry, 2010, 167, 1499-1507.	7.2	140
122	Chronic Depression. Archives of General Psychiatry, 2005, 62, 513.	12.3	139
123	Bupropion and Naltrexone in Methamphetamine Use Disorder. New England Journal of Medicine, 2021, 384, 140-153.	27.0	139
124	Factors Associated With Health-Related Quality of Life Among Outpatients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2006, 67, 185-195.	2.2	139
125	Dropouts versus completers among chronically depressed outpatients. Journal of Affective Disorders, 2007, 97, 197-202.	4.1	138
126	Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. American Journal of Psychiatry, 2015, 172, 743-750.	7.2	138

#	Article	IF	Citations
127	Relationship between objective and subjective sleep measures in depressed patients and healthy controls. Depression and Anxiety, 1997, 5, 97-102.	4.1	136
128	Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice. Psychotherapy and Psychosomatics, 2006, 75, 139-153.	8.8	136
129	Maximizing the Adequacy of Medication Treatment in Controlled Trials and Clinical Practice: STAR*D Measurement-Based Care. Neuropsychopharmacology, 2007, 32, 2479-2489.	5.4	135
130	Use of Bupropion in Combination with Serotonin Reuptake Inhibitors. Biological Psychiatry, 2006, 59, 203-210.	1.3	132
131	The Treatment of Chronic Depression, Part 2. Journal of Clinical Psychiatry, 1998, 59, 598-607.	2.2	132
132	Predictors of Attrition During Initial (Citalopram) Treatment for Depression: A STAR*D Report. American Journal of Psychiatry, 2007, 164, 1189-1197.	7.2	129
133	Association Between Treatment-Emergent Suicidal Ideation With Citalopram and Polymorphisms Near Cyclic Adenosine Monophosphate Response Element Binding Protein in the STAR*D Study. Archives of General Psychiatry, 2007, 64, 689.	12.3	128
134	Benzodiazepines as antidepressants: Does GABA play a role in depression?. Biological Psychiatry, 1995, 38, 578-591.	1.3	126
135	CYP2C19 variation and citalopram response. Pharmacogenetics and Genomics, 2011, 21, 1-9.	1.5	126
136	Algorithms and Collaborative-care Systems for Depression: Are They Effective and Why?. Biological Psychiatry, 2006, 59, 1029-1038.	1.3	125
137	Insomnia in Patients With Depression: <i>A STAR*D Report</i>. CNS Spectrums, 2010, 15, 394-404.	1.2	125
138	Concurrent anxiety and substance use disorders among outpatients with major depression: Clinical features and effect on treatment outcome. Drug and Alcohol Dependence, 2009, 99, 248-260.	3.2	124
139	Concise Health Risk Tracking Scale. Journal of Clinical Psychiatry, 2011, 72, 757-764.	2.2	124
140	Double-blind Switch Study of Imipramine or Sertraline Treatment of Antidepressant-Resistant Chronic Depression. Archives of General Psychiatry, 2002, 59, 233.	12.3	123
141	Children of Currently Depressed Mothers. Journal of Clinical Psychiatry, 2006, 67, 126-136.	2.2	123
142	Cognitive-Behavioral Analysis System of Psychotherapy as a Maintenance Treatment for Chronic Depression.. Journal of Consulting and Clinical Psychology, 2004, 72, 681-688.	2.0	122
143	Factors that differentiate early vs. later onset of major depression disorder. Psychiatry Research, 2004, 129, 127-140.	3.3	121
144	The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment. Journal of Psychiatric Research, 2015, 61, 1-12.	3.1	121

#	Article	IF	Citations
145	Depression and Chronic Low Back Pain. Spine, 2000, 25, 2566-2571.	2.0	119
146	Association Between Bipolar Spectrum Features and Treatment Outcomes in Outpatients With Major Depressive Disorder. Archives of General Psychiatry, 2010, 68, 351.	12.3	118
147	Cognitive-behavioral group therapy for bulimia. International Journal of Eating Disorders, 1986, 5, 599-615.	4.0	117
148	The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 1999, 38, 1442-1454.	0.5	115
149	Self-Reported Depressive Symptom Measures: Sensitivity to Detecting Change in a Randomized, Controlled Trial of Chronically Depressed, Nonpsychotic Outpatients. Neuropsychopharmacology, 2005, 30, 405-416.	5.4	115
150	Obsessive compulsive symptoms in schizophrenia: Frequency and clinical features. Schizophrenia Research, 2005, 76, 309-316.	2.0	115
151	The Texas Medication Algorithm Project (TMAP) Schizophrenia Algorithms. Journal of Clinical Psychiatry, 1999, 60, 649-657.	2.2	115
152	Validation of Depression Screening Scales in Patients With CKD. American Journal of Kidney Diseases, 2009, 54, 433-439.	1.9	111
153	Flexible treatment strategies in chronic disease: clinical and research implications. Biological Psychiatry, 2000, 48, 605-614.	1.3	110
154	Depression, IV: STAR*D Treatment Trial for Depression. American Journal of Psychiatry, 2003, 160, 237-237.	7.2	109
155	Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. General Hospital Psychiatry, 2004, 26, 421-429.	2.4	109
156	Recurrence of Major Depressive Disorder in Hospitalized Children and Adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 1997, 36, 785-792.	0.5	108
157	Validity of Electronically Monitored Medication Adherence and Conventional Adherence Measures in Schizophrenia. Psychiatric Services, 2007, 58, 844-847.	2.0	108
158	Cognitive biases and depression.. Journal of Abnormal Psychology, 1989, 98, 263-267.	1.9	107
159	Comparison of Self-Report and Clinician Ratings on Two Inventories of Depressive Symptomatology. Psychiatric Services, 2006, 57, 829-837.	2.0	106
160	Clinical and Demographic Factors Associated With DSM-IV Melancholic Depression. Annals of Clinical Psychiatry, 2006, 18, 91-98.	0.6	105
161	Association of Polymorphisms in Genes Regulating the Corticotropin-Releasing Factor System With Antidepressant Treatment Response. Archives of General Psychiatry, 2010, 67, 369.	12.3	105
162	Psychometric properties of the Quick Inventory of Depressive Symptomatology in adolescents. International Journal of Methods in Psychiatric Research, 2010, 19, 185-194.	2.1	104

#	Article	IF	Citations
163	Increase in Work Productivity of Depressed Individuals With Improvement in Depressive Symptom Severity. American Journal of Psychiatry, 2013, 170, 633-641.	7.2	104
164	Simultaneous rTMS and psychotherapy in major depressive disorder: Clinical outcomes and predictors from a large naturalistic study. Brain Stimulation, 2018, 11, 337-345.	1.6	104
165	A controlled study of cellular immune function in affective disorders before and during somatic therapy. Psychiatry Research, 1985, 15, 185-193.	3.3	103
166	Which depressions respond to placebo?. Psychiatry Research, 1986, 18, 217-226.	3.3	103
167	Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenetics and Genomics, 2009, 19, 666-674.	1.5	103
168	Reduced REM latency predicts response to tricyclic medication in depressed outpatients. Biological Psychiatry, 1989, 26, 61-72.	1.3	102
169	Medication Treatment for the Severely and Persistently Mentally Ill. Journal of Clinical Psychiatry, 1999, 60, 284-291.	2.2	102
170	A Cognitiveâ€"Emotional Biomarker for Predicting Remission with Antidepressant Medications: A Report from the iSPOT-D Trial. Neuropsychopharmacology, 2015, 40, 1332-1342.	5.4	101
171	Low plasma Î³-aminobutyric acid levels in male patients with depression. Biological Psychiatry, 1992, 32, 354-363.	1.3	100
172	Low Plasma GABA Is a Trait-Like Marker for Bipolar Illness. Neuropsychopharmacology, 1993, 9, 125-132.	5.4	100
173	Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence. JAMA - Journal of the American Medical Association, 2017, 318, 1876.	7.4	99
174	The Effects of Nefazodone on Sleep Architecture in Depression. Neuropsychopharmacology, 1994, 10, 123-127.	5.4	97
175	Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disorders, 2001, 3, 259-265.	1.9	97
176	Clinical, cognitive, and demographic predictors of response to cognitive therapy for depression: A preliminary report. Psychiatry Research, 1991, 37, 245-260.	3.3	96
177	The Stanley Foundation Bipolar Network. British Journal of Psychiatry, 2001, 178, s169-s176.	2.8	96
178	Symptom features of postpartum depression: are they distinct?. Depression and Anxiety, 2008, 25, 20-26.	4.1	96
179	The Cost Consequences of Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2004, 65, 341-347.	2.2	96
180	The Effects of Psychotherapy, Nefazodone, and Their Combination on Subjective Assessment of Disturbed Sleep in Chronic Depression. Sleep, 2003, 26, 130-136.	1.1	95

#	Article	IF	Citations
181	Presenting characteristics of depressed outpatients as a function of recurrence: Preliminary findings from the STAR*D clinical trial. Journal of Psychiatric Research, 2006, 40, 59-69.	3.1	95
182	Brief Psychiatric Rating Scale Expanded Version: How do new items affect factor structure?. Psychiatry Research, 2005, 135, 217-228.	3.3	94
183	One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biological Psychiatry, 2004, 56, 46-53.	1.3	93
184	Major Depression Symptoms in Primary Care and Psychiatric Care Settings: A Cross-Sectional Analysis. Annals of Family Medicine, 2007, 5, 126-134.	1.9	92
185	Durability of antidepressant response to vagus nerve stimulation (VNS). International Journal of Neuropsychopharmacology, 2007, 10, 817-26.	2.1	92
186	Primary Versus Specialty Care Outcomes for Depressed Outpatients Managed with Measurement-Based Care: Results from STAR*D. Journal of General Internal Medicine, 2008, 23, 551-560.	2.6	92
187	Pharmacogenetic Analysis of Genes Implicated in Rodent Models of Antidepressant Response: Association of TREK1 and Treatment Resistance in the STAR*D Study. Neuropsychopharmacology, 2008, 33, 2810-2819.	5.4	92
188	Texas Medication Algorithm Project, Phase 3 (TMAP-3). Journal of Clinical Psychiatry, 2003, 64, 357-369.	2.2	92
189	Response to a Selective Serotonin Reuptake Inhibitor (Citalopram) in Major Depressive Disorder With Melancholic Features. Journal of Clinical Psychiatry, 2008, 69, 1847-1855.	2.2	91
190	Polysomnographic parameters in first-degree relatives of unipolar probands. Psychiatry Research, 1989, 27, 127-136.	3.3	89
191	Group versus individual cognitive therapy: A pilot study. Cognitive Therapy and Research, 1981, 5, 95-103.	1.9	88
192	Genetic and Clinical Predictors of Sexual Dysfunction in Citalopram-Treated Depressed Patients. Neuropsychopharmacology, 2009, 34, 1819-1828.	5.4	88
193	Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: An examination of citalopram in the STARâŽD study. Journal of Affective Disorders, 2009, 117, 63-73.	4.1	88
194	Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Translational Psychiatry, 2013, 3, e223-e223.	4.8	88
195	Slow-wave activity during non-REM sleep in men with schizophrenia and major depressive disorders. Psychiatry Research, 2000, 95, 215-225.	3.3	87
196	Plasma GABA levels correlate with aggressiveness in relatives of patients with unipolar depressive disorder. Psychiatry Research, 2001, 101, 131-136.	3.3	87
197	Implementing practice guidelines for depression: Applying a new framework to an old problem. General Hospital Psychiatry, 2002, 24, 35-42.	2.4	87
198	Methodological Challenges in Constructing Effective Treatment Sequences for Chronic Psychiatric Disorders. Neuropsychopharmacology, 2007, 32, 257-262.	5.4	87

#	Article	IF	Citations
199	Do thinking patterns predict depressive symptoms?. Cognitive Therapy and Research, 1986, 10, 225-235.	1.9	85
200	A Randomized Trial of Citalopram versus Placebo in Outpatients with Asthma and Major Depressive Disorder: A Proof of Concept Study. Biological Psychiatry, 2005, 58, 865-870.	1.3	84
201	Texas Medication Algorithm Project, Phase 3 (TMAP-3). Journal of Clinical Psychiatry, 2003, 64, 370-382.	2.2	84
202	Substance Use Disorder Comorbidity in Major Depressive Disorder: A Confirmatory Analysis of the STAR*D Cohort. American Journal on Addictions, 2006, 15, 278-285.	1.4	83
203	A Randomized, Double‐Blind, Placebo‐Controlled Pilot Study of Naltrexone in Outpatients With Bipolar Disorder and Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2009, 33, 1863-1869.	2.4	83
204	A Multicenter, Double-Blind Comparison of the Effects of Nefazodone and Fluoxetine on Sleep Architecture and Quality of Sleep in Depressed Outpatients. Journal of Clinical Psychopharmacology, 1997, 17, 161-168.	1.4	83
205	Course and Severity of Maternal Depression: Associations with Family Functioning and Child Adjustment. Journal of Youth and Adolescence, 2008, 37, 906-916.	3.5	81
206	Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. Acta Psychiatrica Scandinavica, 2009, 119, 282-289.	4.5	81
207	Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced) Tj ETQq1 1 0.784314 rgBT /O	4.5	81
208	Differential effects of cognitive therapy and pharmacotherapy on depressive symptoms. Journal of Affective Disorders, 1981, 3, 221-229.	4.1	80
209	Risk factors in families of unipolar depression. I. Psychiatric illness and reduced REM latency. Journal of Affective Disorders, 1988, 14, 51-59.	4.1	79
210	Sleep polysomnography as a predictor of recurrence in children and adolescents with major depressive disorder. International Journal of Neuropsychopharmacology, 2001, 4, 159-68.	2.1	79
211	Short-Term Psychotherapy of Depressive Disorders. Psychiatry (New York), 1994, 57, 115-132.	0.7	78
212	Toward a generalizable model of symptoms in major depressive disorder. Biological Psychiatry, 1998, 44, 959-972.	1.3	78
213	High Frequency EEG Activity during Sleep: Characteristics in Schizophrenia and Depression. Clinical EEG and Neuroscience, 2005, 36, 25-35.	1.7	78
214	Randomized, Placebo-Controlled Trial of Fluoxetine for Acute Treatment of Minor Depressive Disorder. American Journal of Psychiatry, 2004, 161, 1864-1871.	7.2	77
215	The Texas Medication Algorithm Project: Clinical Results for Schizophrenia. Schizophrenia Bulletin, 2004, 30, 627-647.	4.3	77
216	Assessing insomnia severity in depression: comparison of depression rating scales and sleep diaries. Journal of Psychiatric Research, 2005, 39, 481-488.	3.1	74

#	Article	IF	Citations
217	Temporal Characteristics of Delta Activity During NREM Sleep in Depressed Outpatients and Healthy Adults: Group and Sex Effects. Sleep, 2000, 23, 1-11.	1.1	73
218	Self-reported premenstrual exacerbation of depressive symptoms in patients seeking treatment for major depression. Psychological Medicine, 2005, 35, 683-692.	4.5	73
219	Pain in depression: STAR*D study findings. Journal of Psychosomatic Research, 2007, 63, 113-122.	2.6	73
220	Weight change in depression. Psychiatry Research, 1986, 17, 275-283.	3.3	71
221	Sleep EEG features of adolescents with major depression. Biological Psychiatry, 1994, 36, 573-581.	1.3	71
222	Clinical differences among depressed patients with and without a history of suicide attempts: Findings from the STARâŽD trial. Journal of Affective Disorders, 2007, 97, 77-84.	4.1	71
223	Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug and Alcohol Dependence, 2010, 107, 161-170.	3.2	71
224	Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression. American Journal of Psychiatry, 2016, 173, 107-111.	7.2	71
225	Dexamethasone response, thyrotropin-releasing hormone stimulation, rapid eye movement latency, and subtypes of depression. Biological Psychiatry, 1997, 41, 915-928.	1.3	70
226	VAGUS NERVE STIMULATION. Psychiatric Clinics of North America, 2000, 23, 757-783.	1.3	70
227	Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology, 2007, 32, 843-853.	2.7	70
228	Randomized, Placebo-Controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biological Psychiatry, 2003, 54, 806-817.	1.3	69
229	Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results. Psychiatric Services, 2009, 60, 1446-1457.	2.0	69
230	What predicts attrition in second step medication treatments for depression?: a STAR*D Report. International Journal of Neuropsychopharmacology, 2009, 12, 459.	2.1	69
231	Pharmacogenomicsâ€Driven Prediction of Antidepressant Treatment Outcomes: A Machineâ€Learning Approach With Multiâ€trial Replication. Clinical Pharmacology and Therapeutics, 2019, 106, 855-865.	4.7	69
232	Acceptability of Second-Step Treatments to Depressed Outpatients: A STAR*D Report. American Journal of Psychiatry, 2007, 164, 753-760.	7.2	68
233	Family history of mood disorder and characteristics of major depressive disorder: A STARâˆ—D (sequenced treatment alternatives to relieve depression) study. Journal of Psychiatric Research, 2007, 41, 214-221.	3.1	67
234	Treating Depression to Remission. Psychiatric Annals, 1995, 25, 704-709.	0.1	67

#	Article	IF	Citations
235	Depression in Asthma: Prevalence and Clinical Implications. Primary Care Companion To the Journal of Clinical Psychiatry, 2000, 02, 153-158.	0.6	67
236	Delta sleep EEG in depressed adolescent females and healthy controls. Journal of Affective Disorders, 2001, 63, 139-148.	4.1	66
237	Psychiatric Symptomatology and Disorders in Caregivers of Children With Asthma. Pediatrics, 2006, 118, e1715-e1720.	2.1	66
238	It Is Time to Take a Stand for Medical Research and Against Terrorism Targeting Medical Scientists. Biological Psychiatry, 2008, 63, 725-727.	1.3	65
239	Variations of Weight Loss Following Gastric Bypass and Gastric Band. Annals of Surgery, 2008, 248, 233-242.	4.2	65
240	Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: Results from the CO-MED trial. European Neuropsychopharmacology, 2012, 22, 183-199.	0.7	65
241	Paroxetine as a Treatment for Premenstrual Dysphoric Disorder. Journal of Clinical Psychopharmacology, 1996, 16, 3-8.	1.4	65
242	Prevalence and Clinical Correlates of Irritability in Major Depressive Disorder. Journal of Clinical Psychiatry, 2005, 66, 159-166.	2.2	65
243	Clinical Practice Guidelines. Archives of General Psychiatry, 1993, 50, 483.	12.3	64
244	The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF). Journal of Psychiatric Research, 2019, 113, 125-136.	3.1	64
245	A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. Medical Devices: Evidence and Research, 2013, 6, 17.	0.8	63
246	Difficult-to-treat depression: A clinical and research roadmap for when remission is elusive. Australian and New Zealand Journal of Psychiatry, 2019, 53, 109-118.	2.3	63
247	The Effects of Fluoxetine on the Polysomnogram of Depressed Outpatients: A Pilot Study. Neuropsychopharmacology, 1994, 10, 85-91.	5.4	62
248	Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disorders, 2002, 4, 283-289.	1.9	62
249	A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial. General Hospital Psychiatry, 2005, 27, 87-96.	2.4	62
250	Preadult onset vs. adult onset of major depressive disorder: a replication study. Acta Psychiatrica Scandinavica, 2007, 115, 196-205.	4.5	62
251	A Trial of Compliance Therapy in Outpatients With Schizophrenia or Schizoaffective Disorder. Journal of Clinical Psychiatry, 2005, 66, 997-1001.	2.2	62
252	Tridimensional personality questionnaire and serotonin in bulimia nervosa. Psychiatry Research, 1993, 48, 9-15.	3.3	61

#	Article	IF	Citations
253	Ultradian rhythms and temporal coherence in sleep EEG in depressed children and adolescents. Biological Psychiatry, 2000, 47, 338-350.	1.3	61
254	Vagus nerve stimulation (VNS): utility in neuropsychiatric disorders. International Journal of Neuropsychopharmacology, 2003, 6, 73-83.	2.1	61
255	Remission of Maternal Depression: Relations to Family Functioning and Youth Internalizing and Externalizing Symptoms. Journal of Clinical Child and Adolescent Psychology, 2008, 37, 714-724.	3.4	60
256	Association of Depressive Symptoms with Hippocampal Volume in 1936 Adults. Neuropsychopharmacology, 2014, 39, 770-779.	5.4	59
257	Biological rhythm disturbance in depression: temporal coherence of ultradian sleep EEG rhythms. Psychological Medicine, 1999, 29, 1435-1448.	4.5	58
258	Sertraline versus imipramine to prevent relapse in chronic depression. Journal of Affective Disorders, 2001, 65, 27-36.	4.1	58
259	Concise Associated Symptoms Tracking Scale. Journal of Clinical Psychiatry, 2011, 72, 765-774.	2.2	58
260	Cognitive and behavior therapy in chronic depression. Behavior Therapy, 1975, 6, 398-404.	2.4	57
261	Digital period analysis of sleep EEG in depression. Biological Psychiatry, 1992, 31, 52-68.	1.3	57
262	Effects of Fluoxetine on the Polysomnogram in Outpatients with Major Depression. Neuropsychopharmacology, 1999, 20, 447-459.	5.4	57
263	An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder. Schizophrenia Research, 2006, 81, 311-316.	2.0	57
264	Fluoxetine and Oculomotor Activity during Sleep in Depressed Patients. Neuropsychopharmacology, 1995, 12, 159-165.	5.4	56
265	Comorbid disorders in patients with bipolar disorder and concomitant substance dependence. Journal of Affective Disorders, 2007, 102, 281-287.	4.1	56
266	Clinical Features of Depression in Outpatients With and Without Co-Occurring General Medical Conditions in STAR*D. Primary Care Companion To the Journal of Clinical Psychiatry, 2007, 09, 7-15.	0.6	56
267	Cocaine and Amphetamine Use in Patients With Psychiatric Illness. Journal of Clinical Psychopharmacology, 2003, 23, 384-388.	1.4	55
268	Lamotrigine for bipolar disorder and comorbid cocaine dependence: A replication and extension study. Journal of Affective Disorders, 2006, 93, 219-222.	4.1	54
269	Ethnicity/Race and Outcome in the Treatment of Depression. Medical Care, 2007, 45, 1043-1051.	2.4	54
270	Alprazolam vs Amitriptyline in Depressions With Reduced REM Latencies. Archives of General Psychiatry, 1985, 42, 1154.	12.3	53

#	Article	IF	Citations
271	Which endogenous depressive symptoms relate to REM latency reduction?. Biological Psychiatry, 1986, 21, 473-482.	1.3	53
272	Magnetic Resonance Imaging Measures of Brain Structure to Predict Antidepressant Treatment Outcome in Major Depressive Disorder. EBioMedicine, 2015, 2, 37-45.	6.1	53
273	Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. Translational Psychiatry, 2019, 9, 173.	4.8	53
274	Do Bupropion SR and Sertraline Differ in Their Effects on Anxiety in Depressed Patients?. Journal of Clinical Psychiatry, 2001, 62, 776-781.	2.2	53
275	Age-Related Characteristics of Depression: A Preliminary STAR*D Report. American Journal of Geriatric Psychiatry, 2005, 13, 852-860.	1.2	52
276	Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophrenia Research, 2006, 86, 244-250.	2.0	52
277	Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report. Psychological Medicine, 2012, 42, 1131-1149.	4.5	52
278	The varied clinical presentations of major depressive disorder. Journal of Clinical Psychiatry, 2007, 68 Suppl 8, 4-10.	2.2	52
279	Is there a role for continuation phase cognitive therapy for depressed outpatients?. Journal of Consulting and Clinical Psychology, 1998, 66, 1036-1040.	2.0	51
280	Chronic Vagus Nerve Stimulation Significantly Improves Quality of Life in Treatment-Resistant Major Depression. Journal of Clinical Psychiatry, 2018, 79, .	2.2	51
281	Bulimia and depression. Journal of Affective Disorders, 1985, 9, 231-238.	4.1	50
282	Folate and Unipolar Depression. Journal of Alternative and Complementary Medicine, 2008, 14, 277-285.	2.1	50
283	Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone.. Journal of Consulting and Clinical Psychology, 2008, 76, 459-467.	2.0	50
284	Do atypical features affect outcome in depressed outpatients treated with citalopram?. International Journal of Neuropsychopharmacology, 2010, 13, 15.	2.1	50
285	Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depression. Psychological Medicine, 2010, 40, 415-424.	4.5	50
286	Pharmacogenetics Studies in STAR*D: Strengths, Limitations, and Results. Psychiatric Services, 2009, 60, 1446-57.	2.0	50
287	Polysomnographic findings and dexamethasone nonsuppression in unipolar depression: A replication and extension. Biological Psychiatry, 1987, 22, 872-882.	1.3	49
288	Clinical characteristics of outpatients with chronic major depression. Journal of Affective Disorders, 1995, 34, 25-32.	4.1	49

#	Article	IF	Citations
289	Clinical issues in considering vagus nerve stimulation for treatment-resistant depression. Experimental Neurology, 2009, 219, 36-43.	4.1	49
290	A pilot study of the treatment of outpatients with chronic pain: Symptom control, stimulus control and social system intervention. Pain, 1978, 5, 163-172.	4.2	48
291	The Relationship between Serum Prolactin Level and Sexual Functioning among Male Outpatients with Schizophrenia or Schizoaffective Disorder: A Randomized Double-Blind Trial of Risperidone vs. Quetiapine. Journal of Sex and Marital Therapy, 2007, 33, 203-216.	1.5	48
292	Depression in radiation oncology patients: a preliminary evaluation. Journal of Affective Disorders, 1998, 50, 17-21.	4.1	47
293	Patient's therapeutic skill acquisition and response to psychotherapy, alone or in combination with medication. Psychological Medicine, 2003, 33, 693-702.	4.5	47
294	DSM Melancholic Features Are Unreliable Predictors of ECT Response. Journal of ECT, 2007, 23, 139-146.	0.6	47
295	Clinical vs. self-report versions of the quick inventory of depressive symptomatology in a public sector sample. Journal of Psychiatric Research, 2007, 41, 239-246.	3.1	47
296	The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women. Menopause, 2010, 17, 828-839.	2.0	47
297	Relationship Between Obesity and Depression. Psychosomatic Medicine, 2013, 75, 863-872.	2.0	47
298	When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips. American Journal of Psychiatry, 2018, 175, 1176-1184.	7.2	47
299	Compliance With Pharmacotherapy in Mood Disorders. Psychiatric Annals, 1995, 25, 269-279.	0.1	47
300	Texas Medication Algorithm Project. Journal of Clinical Psychiatry, 2001, 62, 439-447.	2.2	47
301	Can state and trait variables be disentangled? A methodological framework for psychiatric disorders. Psychiatry Research, 1994, 52, 55-69.	3.3	46
302	Sex differences in the distribution of EEG frequencies during sleep: unipolar depressed outpatients. Journal of Affective Disorders, 1995, 34, 121-129.	4.1	46
303	Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. Translational Psychiatry, 2021, 11, 153.	4.8	46
304	Plasma GABA predicts acute response to divalproex in mania. Biological Psychiatry, 1996, 39, 278-284.	1.3	45
305	Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline. Neuropsychopharmacology, 2001, 25, 131-138.	5.4	45
306	Prevalence of Incompletely Penetrant Huntington's Disease Alleles Among Individuals With Major Depressive Disorder. American Journal of Psychiatry, 2010, 167, 574-579.	7.2	45

#	Article	IF	Citations
307	Factor structure and dimensionality of the two depression scales in STAR*D using level 1 datasets. Journal of Affective Disorders, 2011, 132, 396-400.	4.1	45
308	Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: A CO-MED report. Journal of Affective Disorders, 2011, 133, 467-476.	4.1	45
309	Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED Trial Report. Psychological Medicine, 2013, 43, 945-960.	4.5	45
310	Perception of social interactions in depressed psychiatric patients.. Journal of Consulting and Clinical Psychology, 1982, 50, 209-212.	2.0	44
311	National institute of mental health workshop report on the treatment of bipolar disorder. Biological Psychiatry, 1996, 40, 215-220.	1.3	44
312	Therapist Variables That Predict Symptom Change in Psychotherapy With Chronically Depressed Outpatients.. Psychotherapy, 2004, 41, 255-265.	1.2	44
313	An Open Pilot Study of the Combination of Escitalopram and Bupropion-SR for Outpatients with Major Depressive Disorder. Journal of Psychiatric Practice, 2008, 14, 271-280.	0.7	44
314	On the psychometric validity of the domains of the PDSQ: An illustration of the bi-factor item response theory model. Journal of Psychiatric Research, 2009, 43, 401-410.	3.1	44
315	Income and attrition in the treatment of depression: a STAR*D report. Depression and Anxiety, 2009, 26, 622-633.	4.1	44
316	Effect of Antidepressant Medication Treatment on Suicidal Ideation and Behavior in a Randomized Trial. Journal of Clinical Psychiatry, 2011, 72, 1322-1332.	2.2	44
317	Impact of Structured Clinical Interviews on Physicians' Practices in Community Mental Health Settings. Psychiatric Services, 2003, 54, 712-718.	2.0	43
318	Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. Psychological Medicine, 2005, 35, 1695-1706.	4.5	43
319	Health Impacts of Caregiving for Older Adults With Functional Limitations. Journal of Aging and Health, 2013, 25, 998-1012.	1.7	43
320	Age-Related Characteristics of Depression: A Preliminary STAR*D Report. American Journal of Geriatric Psychiatry, 2005, 13, 852-860.	1.2	43
321	The Treatment of Chronic Depression, Part 1. Journal of Clinical Psychiatry, 1998, 59, 589-597.	2.2	43
322	Neuropsychological dysfunctions in unipolar nonpsychotic major depressions. Journal of Affective Disorders, 1983, 5, 281-287.	4.1	42
323	Free triiodothyronine (T3) and thyroxine (T4) in a group of unipolar depressed patients and normal subjects. Biological Psychiatry, 1985, 20, 1047-1054.	1.3	42
324	Stability of plasma GABA at four-year follow-up in patients with primary unipolar depression. Biological Psychiatry, 1995, 37, 806-810.	1.3	42

#	Article	IF	Citations
325	Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project. Clinical Trials, 2004, 1, 387-398.	1.6	42
326	Naltrexone in patients with bipolar disorder and alcohol dependence. Depression and Anxiety, 2006, 23, 492-495.	4.1	42
327	Outcomes on the pharmacopsychometric triangle in bupropion€SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatrica Scandinavica, 2012, 125, 342-348.	4.5	42
328	Recursive Subsetting to Identify Patients in the STAR*D. Journal of Clinical Psychiatry, 2010, 71, 1502-1508.	2.2	42
329	Cognitive Response Test. Cognitive Therapy and Research, 1983, 7, 425-435.	1.9	41
330	Does the pretreatment polysomnogram predict response to cognitive therapy in depressed outpatients? A preliminary report. Psychiatry Research, 1990, 33, 285-299.	3.3	41
331	Sleep electroencephalographic coherence abnormalities in individuals at high risk for depression: a pilot study. Biological Psychiatry, 2000, 47, 618-625.	1.3	41
332	Visual contrast sensitivity in major depressive disorder. Journal of Psychosomatic Research, 2013, 75, 83-86.	2.6	41
333	A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in Patients with Bipolar Disorder, Mixed or Depressed Phase, and Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2014, 38, 2113-2118.	2.4	41
334	Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression. American Journal of Psychiatry, 2016, 173, 481-490.	7.2	41
335	Vagus nerve stimulation in depression. Expert Opinion on Pharmacotherapy, 2001, 2, 1061-1063.	1.8	40
336	Ketoconazole in bipolar patients with depressive symptoms: a case series and literature review. Bipolar Disorders, 2001, 3, 23-29.	1.9	40
337	An Open-Label Trial of Quetiapine for Antipsychotic-Induced Sexual Dysfunction. Journal of Sex and Marital Therapy, 2004, 30, 325-332.	1.5	40
338	A Psychometric Evaluation of the CDRS and MADRS in Assessing Depressive Symptoms in Children. Journal of the American Academy of Child and Adolescent Psychiatry, 2007, 46, 1204-1212.	0.5	40
339	Treatment Outcomes for Older Depressed Patients With Earlier Versus Late Onset of First Depressive Episode: A Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Report. American Journal of Geriatric Psychiatry, 2008, 16, 58-64.	1.2	40
340	Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial. American Journal of Psychiatry, 2016, 173, 1196-1204.	7.2	40
341	What moderator characteristics are associated with better prognosis for depression?. Neuropsychiatric Disease and Treatment, 2005, 1, 51-57.	2.2	40
342	The Stanley Foundation Bipolar Network. British Journal of Psychiatry, 2001, 178, s177-s183.	2.8	39

#	Article	IF	Citations
343	A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial. Psychotherapy and Psychosomatics, 2018, 87, 285-295.	8.8	39
344	Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. American Journal of Psychiatry, 2019, 176, 358-366.	7.2	39
345	Does the Duration of Index Episode Affect the Treatment Outcome of Major Depressive Disorder?. Journal of Clinical Psychiatry, 2008, 69, 1246-1256.	2.2	39
346	Membrane biophysical studies of lymphocytes and erythrocytes in manic-depressive illness. Journal of Affective Disorders, 1982, 4, 237-247.	4.1	37
347	Comparison of the delta EEG in the first and second non-REM periods in depressed adults and normal control. Psychiatry Research, 1992, 41, 65-72.	3.3	37
348	Prediction of response to fluoxetine and placebo in children and adolescents with major depression: a hypothesis generating study1Presented at the American Academy of Child and Adolescent Psychiatry 42nd Annual Meeting, New Orleans, LA, 19 October 1995.1. Journal of Affective Disorders, 1999, 54, 269-276.	4.1	37
349	The effects of vagus nerve stimulation on sleep EEG in depression. Journal of Psychosomatic Research, 2003, 54, 475-482.	2.6	37
350	Constructing evidence-based treatment strategies using methods from computer science. Drug and Alcohol Dependence, 2007, 88, S52-S60.	3.2	37
351	Improving Depression Outcome by Patient-Centered Medical Management. American Journal of Psychiatry, 2018, 175, 1187-1198.	7.2	37
352	Targeting Treatments to Improve Cognitive Function in Mood Disorder. Journal of Clinical Psychiatry, 2016, 77, e1639-e1646.	2.2	37
353	Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature. Scientific Reports, 2021, 11, 21011.	3.3	37
354	Prospective assessment of electroencephalograpic sleep in remitted major depression. Psychiatry Research, 1993, 46, 269-284.	3.3	36
355	Platelet alpha2A-adrenoceptor function in major depression: Gi coupling, effects of imipramine and relationship to treatment outcome. Psychiatry Research, 1999, 89, 73-95.	3.3	36
356	Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. Journal of Psychopharmacology, 2012, 26, 360-367.	4.0	36
357	Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: Implications for the Research Domain Criteria (RDoC). Journal of Affective Disorders, 2014, 163, 18-24.	4.1	36
358	Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. Journal of Affective Disorders, 2020, 264, 90-97.	4.1	36
359	Diurnal Mood Variation in Outpatients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2007, 68, 1339-1347.	2.2	36
360	Oral contraceptives and depressive symptomatology: Biologic mechanisms. Comprehensive Psychiatry, 1979, 20, 347-358.	3.1	35

#	Article	IF	Citations
361	TRH-induced prolactin release is blunted in females with endogenous unipolar major depression. Psychiatry Research, 1984, 12, 321-331.	3.3	35
362	Clinical and Sociodemographic Characteristics Associated with Suicidal Ideation in Depressed Outpatients. Canadian Journal of Psychiatry, 2013, 58, 113-122.	1.9	35
363	A New Empirical Definition of Major Depressive Episode Recovery and Its Positive Impact on Future Course of Illness. Journal of Clinical Psychiatry, 2016, 77, 1065-1073.	2.2	35
364	The effect of dosage on the dexamethasone suppression test in normal controls. Psychiatry Research, 1982, 7, 277-285.	3.3	34
365	Electronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of its reliability and predictive validity. Psychiatry Research, 2008, 157, 259-263.	3.3	34
366	The Quick Inventory of Depressive Symptomatology-Self-report: a psychometric evaluation in patients with asthma and major depressive disorder. Annals of Allergy, Asthma and Immunology, 2008, 100, 433-438.	1.0	34
367	Do Menopausal Status and Use of Hormone Therapy Affect Antidepressant Treatment Response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study. Journal of Women's Health, 2013, 22, 121-131.	3.3	34
368	Clinical research challenges posed by difficult-to-treat depression. Psychological Medicine, 2022, 52, 419-432.	4.5	34
369	Making clinicians lives easier: Guidance on use of the QIDS self-report in place of the MADRS. Journal of Affective Disorders, 2006, 95, 115-118.	4.1	33
370	Diagnostic utility of the Quick Inventory of Depressive Symptomatology (QIDSâ€€₁₆ and) Tj ETQq0 0 0 rgBT /Overlock 10	4.5	33
371	Depression Treatment in Patients With General Medical Conditions: Results From the CO-MED Trial. Annals of Family Medicine, 2012, 10, 23-33.	1.9	33
372	VitalSign6: A Primary Care First (PCP-First) Model for Universal Screening and Measurement-Based Care for Depression. Pharmaceuticals, 2019, 12, 71.	3.8	33
373	Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: an iSPOT-D report. Translational Psychiatry, 2021, 11, 417.	4.8	33
374	The Efficacy of Acute Electroconvulsive Therapy in Atypical Depression. Journal of Clinical Psychiatry, 2008, 69, 406-411.	2.2	33
375	Metabolomic and inflammatory signatures of symptom dimensions in major depression. Brain, Behavior, and Immunity, 2022, 102, 42-52.	4.1	33
376	Depression: Must pharmacotherapy fail for cognitive therapy to succeed?. Cognitive Therapy and Research, 1978, 2, 199-206.	1.9	32
377	Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients. Psychiatry Research, 1994, 52, 327-339.	3.3	32
378	Sleep microarchitecture as a predictor of recurrence in children and adolescents with depression. International Journal of Neuropsychopharmacology, 2002, 5, 217-28.	2.1	32

#	Article	IF	Citations
379	Bupropion in the Treatment of Outpatients with Asthma and Major Depressive Disorder. International Journal of Psychiatry in Medicine, 2007, 37, 23-28.	1.8	32
380	Isnâ€™t It About Time to Employ Measurement-Based Care in Practice?. American Journal of Psychiatry, 2015, 172, 934-936.	7.2	32
381	Psychometric properties of the concise health risk tracking (CHRT) in adolescents with suicidality. Journal of Affective Disorders, 2018, 235, 45-51.	4.1	32
382	A Structured Approach to Detecting and Treating Depression in Primary Care: VitalSign6 Project. Annals of Family Medicine, 2019, 17, 326-335.	1.9	32
383	Digital period analysis of EEG in depression: Periodicity, coherence, and interhemispheric relationships during sleep. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1993, 17, 363-372.	4.8	31
384	Escitalopram in clinical practice: Results of an open-label trial in a naturalistic setting. Depression and Anxiety, 2005, 21, 26-32.	4.1	31
385	Star-D: lessons learned and future implications. Depression and Anxiety, 2011, 28, 521-524.	4.1	31
386	Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes. American Journal of Nephrology, 2019, 50, 37-47.	3.1	31
387	Age-adjusted threshold values for reduced REM latency in unipolar depression using ROC analysis. Biological Psychiatry, 1990, 27, 841-853.	1.3	30
388	Does pretreatment anxiety predict response to either bupropion SR or sertraline?. Journal of Affective Disorders, 2001, 64, 81-87.	4.1	30
389	Major Depressive Disorder and Comorbid Cardiac Disease: Is There a Depressive Subtype With Greater Cardiovascular Morbidity? Results From the STAR*D Study. Psychosomatics, 2007, 48, 418-425.	2.5	30
390	A Comparison of the QIDS-C$_{16}$, QIDS-SR$_{16}$, and the MADRS in an Adult Outpatient Clinical Sample. CNS Spectrums, 2010, 15, 458-468.	1.2	30
391	Effects of Race and Ethnicity on Depression Treatment Outcomes: The CO-MED Trial. Psychiatric Services, 2011, 62, 1167-1179.	2.0	30
392	A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline for Cocaine Dependence in Bipolar I Disorder. American Journal of Psychiatry, 2015, 172, 1014-1021.	7.2	30
393	Comparison between Clinician-Rated and Self-Reported Depressive Symptoms in Italian Psychiatric Patients. Neuropsychobiology, 1988, 19, 1-5.	1.9	29
394	Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department. International Clinical Psychopharmacology, 1999, 14, 361-372.	1.7	29
395	Prediction of Nonremission to Antidepressant Therapy Using Diffusion Tensor Imaging. Journal of Clinical Psychiatry, 2016, 77, e436-e443.	2.2	29
396	Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. Psychopharmacology Bulletin, 2003, 37, 73-87.	0.0	29

#	Article	IF	Citations
397	Effect of two prednisone exposures on mood and declarative memory. Neurobiology of Learning and Memory, 2006, 86, 28-34.	1.9	28
398	Remission of maternal depression and child symptoms among single mothers. Social Psychiatry and Psychiatric Epidemiology, 2007, 42, 962-971.	3.1	28
399	Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR*D trial. Depression and Anxiety, 2009, 26, 612-621.	4.1	28
400	Prediction of treatment outcomes to exercise in patients with nonremitted major depressive disorder. Depression and Anxiety, 2017, 34, 1116-1122.	4.1	28
401	Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. Journal of Affective Disorders, 2018, 238, 1-7.	4.1	28
402	Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 457-468.	2.2	28
403	Limitations in efficacy of antidepressant monotherapy. Journal of Clinical Psychiatry, 2007, 68 Suppl 10, 8-10.	2.2	28
404	A cross-sectional study of the effects of depression on REM latency. Biological Psychiatry, 1990, 28, 697-704.	1.3	27
405	Therapeutic Reactance as a Predictor of Outcome in the Treatment of Chronic Depression.. Journal of Consulting and Clinical Psychology, 2003, 71, 1025-1035.	2.0	27
406	Comparison of Quality of Life Measures in a Depressed Population. Journal of Nervous and Mental Disease, 2007, 195, 219-225.	1.0	27
407	Personalizing antidepressant choice by sex, body mass index, and symptom profile: An iSPOT-D report. Personalized Medicine in Psychiatry, 2017, 1-2, 65-73.	0.1	27
408	Worsening Anxiety, Irritability, Insomnia, or Panic Predicts Poorer Antidepressant Treatment Outcomes: Clinical Utility and Validation of the Concise Associated Symptom Tracking (CAST) Scale. International Journal of Neuropsychopharmacology, 2018, 21, 325-332.	2.1	27
409	Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. Clinical Therapeutics, 1999, 21, 1105-1116.	2.5	26
410	Implementing Guidelines and Systems of Care. Journal of Psychiatric Practice, 1999, 5, 75-86.	0.7	26
411	Catching Up on Health Outcomes: The Texas Medication Algorithm Project. Health Services Research, 2003, 38, 311-331.	2.0	26
412	Characteristics of Insured and Noninsured Outpatients With Depression in STAR*D. Psychiatric Services, 2005, 56, 995-1004.	2.0	26
413	Daily process methodology for measuring earlier antidepressant response. Contemporary Clinical Trials, 2008, 29, 867-877.	1.8	26
414	Depression Outcomes of Spanish- and English-Speaking Hispanic Outpatients in STAR*D. Psychiatric Services, 2008, 59, 1273-1284.	2.0	26

#	Article	IF	Citations
415	The impact of diabetes on depression treatment outcomes. General Hospital Psychiatry, 2010, 32, 33-41.	2.4	26
416	Combining Antidepressant Medications: A Good Idea?. American Journal of Psychiatry, 2010, 167, 241-243.	7.2	26
417	What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?. Depression and Anxiety, 2012, 29, 94-101.	4.1	26
418	Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST). Contemporary Clinical Trials, 2013, 34, 136-144.	1.8	26
419	Adherence to Antidepressant Combinations and Monotherapy for Major Depressive Disorder. Journal of Psychiatric Practice, 2014, 20, 118-132.	0.7	26
420	Early normalization of Quality of Life predicts later remission in depression: Findings from the CO-MED trial. Journal of Affective Disorders, 2016, 206, 17-22.	4.1	26
421	Perception of Stigma and Its Associated Factors Among Patients With Major Depressive Disorder: A Multicenter Survey From an Asian Population. Frontiers in Psychiatry, 2019, 10, 321.	2.6	26
422	Childhood maltreatment and impact on clinical features of major depression in adults. Psychiatry Research, 2020, 293, 113412.	3.3	26
423	Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients. PLoS ONE, 2016, 11, e0167901.	2.5	26
424	Which Depressed Patients Respond to Nefazodone and When?. Journal of Clinical Psychiatry, 2001, 62, 158-163.	2.2	26
425	Regional cerebral blood flow alterations in unipolar depression. Psychiatry Research - Neuroimaging, 1993, 50, 233-256.	1.8	25
426	Identifying Risk for Attrition during Treatment for Depression. Psychotherapy and Psychosomatics, 2009, 78, 372-379.	8.8	25
427	Predictors of Attrition During One Year of Depression Treatment: A Roadmap to Personalized Intervention. Journal of Psychiatric Practice, 2009, 15, 113-124.	0.7	25
428	The Impact of Chronic Depression on Acute and Long-Term Outcomes in a Randomized Trial Comparing Selective Serotonin Reuptake Inhibitor Monotherapy Versus Each of 2 Different Antidepressant Medication Combinations. Journal of Clinical Psychiatry, 2012, 73, 967-976.	2.2	25
429	The effect of lithium on the membrane molecular dynamics of normal human erythrocytes. Biological Psychiatry, 1987, 22, 857-871.	1.3	24
430	Adrenergic receptor function in panic disorder II. Neutrophil β2 receptors: Gs protein coupling, effects of imipramine treatment and relationship to treatment outcome. Journal of Psychiatric Research, 1999, 33, 309-321.	3.1	24
431	Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind pilot trial. Psychiatry Research, 2008, 159, 115-120.	3.3	24
432	A Role for ΔFosB in Calorie Restriction-Induced Metabolic Changes. Biological Psychiatry, 2011, 70, 204-207.	1.3	24

#	Article	IF	Citations
433	Association Between Tea Consumption and Depressive Symptoms in Older Chinese Adults. Journal of the American Geriatrics Society, 2012, 60, 2358-2360.	2.6	24
434	A Brief Clinical Tool to Estimate Individual Patients' Risk of Depressive Relapse Following Remission: Proof of Concept. American Journal of Psychiatry, 2016, 173, 1140-1146.	7.2	24
435	The Texas Medication Algorithm Project Patient and Family Education Program. Journal of Clinical Psychiatry, 2000, 61, 477-486.	2.2	24
436	Adrenergic receptors in premenstrual dysphoric disorder: I. Platelet α2 receptors: Gi protein coupling, phase of menstrual cycle, and prediction of luteal phase symptom severity. Biological Psychiatry, 1998, 44, 600-609.	1.3	23
437	Measuring costs of guideline-driven mental health care: the Texas Medication Algorithm Project. , 1999, 2, 111-121.		23
438	Methodological issues in developing new acute treatments for patients with bipolar illness. Biological Psychiatry, 2000, 48, 615-624.	1.3	23
439	Diurnal mood variation in outpatients with major depressive disorder. Depression and Anxiety, 2009, 26, 851-863.	4.1	23
440	The Clinical Relevance of Self-Reported Premenstrual Worsening of Depressive Symptoms in the Management of Depressed Outpatients: A STAR*D Report. Journal of Women's Health, 2013, 22, 219-229.	3.3	23
441	Ketamine for Treatment-Resistant Depression: Ready or Not for Clinical Use?. American Journal of Psychiatry, 2013, 170, 1079-1081.	7.2	23
442	Can psychological features predict antidepressant response to rTMS? A Discovery–Replication approach. Psychological Medicine, 2020, 50, 264-272.	4.5	23
443	Clinically meaningful changes on depressive symptom measures and patient‐reported outcomes in patients with treatment‐resistant depression. Acta Psychiatrica Scandinavica, 2021, 143, 253-263.	4.5	23
444	Enhancing the Technology of Clinical Trials and the Trials Model to Evaluate Newly Developed, Targeted Antidepressants. Neuropsychopharmacology, 2002, 27, 319-328.	5.4	22
445	Clinical features of depression in Asia: Results of a large prospective, cross-sectional study. Asia-Pacific Psychiatry, 2013, 5, 259-267.	2.2	22
446	Toward an online cognitive and emotional battery to predict treatment remission in depression. Neuropsychiatric Disease and Treatment, 2015, 11, 517.	2.2	22
447	Positive and negative valence systems in major depression have distinct clinical features, response to antidepressants, and relationships with immunomarkers. Depression and Anxiety, 2020, 37, 771-783.	4.1	22
448	Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. Journal of Clinical Psychiatry, 2005, 66, 159-66; quiz 147, 273-4.	2.2	22
449	A Cognitive Model of Anxiety Formation and Anxiety Resolution. Issues in Mental Health Nursing, 1985, 7, 349-365.	1.2	21
450	Persistent cortisol non-suppression after clinical recovery predicts symptomatic relapse in unipolar depression. Journal of Affective Disorders, 1989, 17, 271-278.	4.1	21

#	Article	IF	Citations
451	Enrolling research subjects from clinical practice: Ethical and procedural issues in the Sequenced Treatment Alternatives to Relieve Depression (STARâŽD) trial. Psychiatry Research, 2006, 141, 193-200.	3.3	21
452	Early Adverse Events and Attrition in Selective Serotonin Reuptake Inhibitor Treatment. Journal of Clinical Psychopharmacology, 2010, 30, 259-266.	1.4	21
453	Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. International Journal of Neuropsychopharmacology, 2012, 15, 1387-1399.	2.1	21
454	Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 803-813.	2.2	21
455	Algorithms For Treatment of Major Depressive Disorder: Efficacy and Cost-Effectiveness. Pharmacopsychiatry, 2019, 52, 117-125.	3.3	21
456	Profound and reproducible patterns of reduced regional gray matter characterize major depressive disorder. Translational Psychiatry, 2019, 9, 176.	4.8	21
457	Electronic source materials in clinical research: Acceptability and validity of symptom self-rating in major depressive disorder. Journal of Psychiatric Research, 2007, 41, 737-743.	3.1	20
458	The Quick Inventory of Depressive Symptomatology (Clinician and Self-Report Versions) in Patients With Bipolar Disorder. CNS Spectrums, 2010, 15, 367-373.	1.2	20
459	Gender-specific structural abnormalities in major depressive disorder revealed by fixel-based analysis. NeuroImage: Clinical, 2019, 21, 101668.	2.7	20
460	EEG biomarker informed prescription of antidepressants in MDD: a feasibility trial. European Neuropsychopharmacology, 2021, 44, 14-22.	0.7	20
461	Cognitive Therapy of Depression: Rationale, Techniques, and Efficacy. Psychiatric Clinics of North America, 1983, 6, 105-127.	1.3	20
462	MAOIs in the Contemporary Treatment of Depression. Neuropsychopharmacology, 1995, 12, 185-219.	5.4	20
463	The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry. International Journal of Bipolar Disorders, 2020, 8, 13.	2.2	20
464	Secular trend in unipolar depression: a hypothesis. Journal of Affective Disorders, 1989, 16, 71-75.	4.1	19
465	Impulsivity and neuroendocrine response to buspirone in bulimia nervosa. Biological Psychiatry, 1996, 39, 371-374.	1.3	19
466	Development of the Brief Bipolar Disorder Symptom Scale for patients with bipolar disorder. Psychiatry Research, 2004, 127, 137-145.	3.3	19
467	An Empirical Analysis of Cost Outcomes of the Texas Medication Algorithm Project. Psychiatric Services, 2006, 57, 648-659.	2.0	19
468	Screening for Major Depression in Private Practice. Journal of Psychiatric Practice, 2009, 15, 87-94.	0.7	19

#	Article	IF	Citations
469	Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: A CO-MED report. Journal of Affective Disorders, 2015, 174, 157-164.	4.1	19
470	Speculations on the Future of Psychiatric Diagnosis. Journal of Nervous and Mental Disease, 2018, 206, 481-487.	1.0	19
471	Drug repurposing for opioid use disorders: integration of computational prediction, clinical corroboration, and mechanism of action analyses. Molecular Psychiatry, 2021, 26, 5286-5296.	7.9	19
472	Family History of Depression and Therapeutic Outcome. Journal of Clinical Psychiatry, 2009, 70, 185-195.	2.2	19
473	A one year follow-up of the multimodal treatment for chronic pain. Pain, 1982, 14, 45-52.	4.2	18
474	The thyrotropin-releasing hormone stimulation test: A methodological study. Psychiatry Research, 1983, 9, 59-67.	3.3	18
475	The effects of extended evaluation on depressive symptoms in children and adolescents. Journal of Affective Disorders, 1996, 41, 149-156.	4.1	18
476	Adrenergic receptors in premenstrual dysphoric disorder. II. Neutrophil $\beta2$-adrenergic receptors: Gs protein coupling, phase of menstrual cycle and prediction of luteal phase symptom severity. Psychiatry Research, 1998, 79, 31-42.	3.3	18
477	Adrenergic Receptor Function in Panic Disorder, I. Platelet $\alpha2$ Receptors Gi Protein Coupling, Effects of Imipramine, and Relationship to Treatment Outcome. Neuropsychopharmacology, 1999, 20, 162-176.	5.4	18
478	Skating to where the puck is going to be: a plan for clinical trials and translation research in mood disorders. Biological Psychiatry, 2002, 52, 631-654.	1.3	18
479	A psychometric evaluation of the clinician€rated Quick Inventory of Depressive Symptomatology (QIDS€C₁₆) in patients with bipolar disorder. International Journal of Methods in Psychiatric Research, 2009, 18, 138-146.	2.1	18
480	Implementation of the Texas Medication Algorithm Project Patient and Family Education Program. Journal of Clinical Psychiatry, 2006, 67, 1362-1372.	2.2	18
481	Effects of four normalizing methods on data analytic results in functional brain imaging. Biological Psychiatry, 1996, 40, 1106-1121.	1.3	17
482	Clinician, Parent, and Child Prediction of Medication or Placebo in Double-Blind Depression Study. Neuropsychopharmacology, 2000, 23, 591-594.	5.4	17
483	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Focus (American Psychiatric Publishing), 2008, 6, 128-142.	0.8	17
484	Indicators of pretreatment suicidal ideation in adults with major depressive disorder. Acta Psychiatrica Scandinavica, 2010, 121, 480-484.	4.5	17
485	RETENTION AND ATTRITION AMONG AFRICAN AMERICANS IN THE STAR*D STUDY: WHAT CAUSES RESEARCH VOLUNTEERS TO STAY OR STRAY?. Depression and Anxiety, 2013, 30, 1137-1144.	4.1	17
486	TARGET JNL: Neuropsychiatric Disease and Treatment Clinically Significant Changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 2333-2345.	2.2	17

#	Article	IF	Citations
487	The development of clinical paractice guidelines for the diagnosis and treatment of depression. General Hospital Psychiatry, 1992, 14, 230-236.	2.4	16
488	Structured Interview and Uniform Assessment Improves Diagnostic Reliability. Journal of Child and Adolescent Psychopharmacology, 2000, 10, 119-131.	1.3	16
489	Family history of completed suicide and characteristics of major depressive disorder: A STARâŽD (sequenced treatment alternatives to relieve depression) study. Journal of Affective Disorders, 2008, 108, 129-134.	4.1	16
490	Changes in Depressive Symptoms and Social Functioning in the Sequenced Treatment Alternatives to Relieve Depression Study. Journal of Nervous and Mental Disease, 2011, 199, 807-810.	1.0	16
491	Assessing anxious features in depressed outpatients. International Journal of Methods in Psychiatric Research, 2011, 20, e69-82.	2.1	16
492	A practical approach to the early identification of antidepressant medication non-responders. Psychological Medicine, 2012, 42, 309-316.	4.5	16
493	Impairment and distress patterns distinguishing the melancholic depression subtype: An iSPOT-D report. Journal of Affective Disorders, 2015, 174, 493-502.	4.1	16
494	Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. Journal of Affective Disorders, 2019, 246, 62-68.	4.1	16
495	Distinguishing Functional From Syndromal Recovery: Implications for Clinical Care and Research. Journal of Clinical Psychiatry, 2015, 76, e832-e834.	2.2	16
496	Suppression of cortisol following dexamethasone in demented patients. Psychiatry Research, 1986, 17, 173-182.	3.3	15
497	Does learned resourcefulness predict response to cognitive therapy in depressed outpatients?. Journal of Affective Disorders, 1991, 23, 223-229.	4.1	15
498	The use of placebos in unipolar major depression: the current status. Biological Psychiatry, 2000, 47, 745-747.	1.3	15
499	Psychiatric Emergency Service Use After Implementation of Managed Care in a Public Mental Health System. Psychiatric Services, 2005, 56, 691-698.	2.0	15
500	Assessing the preventive effects of cognitive therapy following relief of depression: A methodological innovation. Journal of Affective Disorders, 2007, 104, 251-261.	4.1	15
501	A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes: A STARâŽD report. Journal of Affective Disorders, 2008, 108, 113-120.	4.1	15
502	The Relationship Between Adverse Events During Selective Serotonin Reuptake Inhibitor Treatment for Major Depressive Disorder and Nonremission in the Suicide Assessment Methodology Study. Journal of Clinical Psychopharmacology, 2011, 31, 31-38.	1.4	15
503	Sensitivity, specificity, and predictive power of the â€œBrief Riskâ€‘resilience Index for SC reening,â€•a brief panâ€‘diagnostic web screen for emotional health. Brain and Behavior, 2012, 2, 576-589.	2.2	15
504	EFFECT OF CONCURRENT SUBSTANCE USE DISORDER ON THE EFFECTIVENESS OF SINGLE AND COMBINATION ANTIDEPRESSANT MEDICATIONS FOR THE TREATMENT OF MAJOR DEPRESSION: AN EXPLORATORY ANALYSIS OF A SINGLE-BLIND RANDOMIZED TRIAL. Depression and Anxiety, 2012, 29, 111-122.	4.1	15

#	Article	IF	Citations
505	Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. Frontiers in Neuroscience, 2019, 13, 926.	2.8	15
506	A prospective, multi-center randomized, controlled, blinded trial of vagus nerve stimulation for difficult to treat depression: A novel design for a novel treatment. Contemporary Clinical Trials, 2020, 95, 106066.	1.8	15
507	The Prevalence and Severity of Depressive Symptoms Along the Spectrum of Unipolar Depressive Disorders. Journal of Clinical Psychiatry, 2013, 74, 1084-1091.	2.2	15
508	Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 3229-3244.	2.2	15
509	Diurnal mood variation in outpatients with major depressive disorder: implications for DSM-V from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study data. Journal of Clinical Psychiatry, 2007, 68, 1339-47.	2.2	15
510	Alprazolam in Bipolarâ€‖ Depressions. Pharmacotherapy, 1984, 4, 40-42.	2.6	14
511	Neutrophil β 2 -adrenergic receptor coupling efficiency to Gs protein in subjects with post-traumatic stress disorder and normal controls. Psychopharmacology, 1999, 143, 131-140.	3.1	14
512	A comparison of alternative assessments of depressive symptom severity: a pilot study. Psychiatry Research, 2000, 95, 55-65.	3.3	14
513	Psychotherapies for Depressive Disorders: A Review. , 2001, , 161-232.		14
514	Differences in psychiatric symptoms among Asian patients with depression: A multi-country cross-sectional study. Psychiatry and Clinical Neurosciences, 2014, 68, 245-254.	1.8	14
515	A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder. Journal of Psychiatric Research, 2018, 102, 65-71.	3.1	14
516	The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients. Journal of Psychopharmacology, 2019, 33, 185-193.	4.0	14
517	Toward a very brief quality of life enjoyment and Satisfaction Questionnaire. Journal of Affective Disorders, 2019, 242, 87-95.	4.1	14
518	Predicting future suicidal events in adolescents using the Concise Health Risk Tracking Self-Report (CHRT-SR). Journal of Psychiatric Research, 2020, 126, 19-25.	3.1	14
519	Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. Neuropsychopharmacology, 2021, 46, 1272-1282.	5.4	14
520	Effect of Structured Interviews on Evaluation Time in Pediatric Community Mental Health Settings. Psychiatric Services, 2005, 56, 1098-1103.	2.0	13
521	Conflict of Interestâ€" An Issue for Every Psychiatrist. American Journal of Psychiatry, 2009, 166, 274-274.	7.2	13
522	A Clinicianâ€™s Perspective on Biomarkers. Focus (American Psychiatric Publishing), 2018, 16, 124-134.	0.8	13

#	Article	IF	Citations
523	New Designs for Studies of the Prophylaxis of Bipolar Disorder. Journal of Clinical Psychopharmacology, 2002, 22, 1-3.	1.4	13
524	Vagus Nerve Stimulation in Patients Receiving Maintenance Therapy With Electroconvulsive Therapy. Journal of ECT, 2021, 37, 84-87.	0.6	13
525	Are Depressed Outpatients With and Without a Family History of Substance Use Disorder Different?. Journal of Clinical Psychiatry, 2007, 68, 1931-1938.	2.2	13
526	Secondary depression: a comparison among subtypes. Journal of Affective Disorders, 1987, 12, 251-258.	4.1	12
527	Platelet Î± 2 -adrenergic receptor coupling efficiency to G i protein in subjects with post-traumatic stress disorder and normal controls. Psychopharmacology, 1999, 141, 258-266.	3.1	12
528	Psychotherapies for Depressive Disorders: A Review. , 2003, , 161-232.		12
529	The Therapeutic Alliance and CBASP-Specific Skill Acquisition in the Treatment of Chronic Depression. Cognitive Therapy and Research, 2005, 29, 803-817.	1.9	12
530	Does Pretreatment Insomnia or Anxiety Predict Acute Response to Bupropion SR?. Annals of Clinical Psychiatry, 2005, 17, 1-9.	0.6	12
531	The Edinburgh Postnatal Depression Scale as a measure for antenatal dysphoria. Journal of Reproductive and Infant Psychology, 2015, 33, 28-41.	1.8	12
532	Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial. Neuropsychopharmacology, 2018, 43, 2197-2203.	5.4	12
533	Item response analysis of the inventory of depressive symptomatology. Neuropsychiatric Disease and Treatment, 2006, 2, 557-564.	2.2	12
534	Clinically Relevant Findings from STAR*D. Psychiatric Annals, 2008, 38, .	0.1	12
535	NeuroBlu, an electronic health record (EHR) trusted research environment (TRE) to support mental healthcare analytics with real-world data. BMJ Open, 2022, 12, e057227.	1.9	12
536	Characteristics of norepinephrine and clonidine displacement of [3H]yohimbine binding to platelet alpha2-adrenoreceptors in healthy volunteers. Psychiatry Research, 1999, 85, 305-314.	3.3	11
537	Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder. Psychological Medicine, 2003, 33, 511-518.	4.5	11
538	The Impact of Nonclinical Factors on Care Use for Patients with Depression: A STAR*D Report. CNS Neuroscience and Therapeutics, 2009, 15, 320-332.	3.9	11
539	Measuring Use and Cost of Care for Patients With Mood Disorders. Medical Care, 2009, 47, 184-190.	2.4	11
540	Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. Journal of Psychiatric Research, 2013, 47, 1199-1203.	3.1	11

#	Article	IF	Citations
541	Estimating Optimal Shared-Parameter Dynamic Regimens with Application to a Multistage Depression Clinical Trial. Biometrics, 2016, 72, 865-876.	1.4	11
542	Factors Associated with Concomitant Psychotropic Drug Use in the Treatment of Major Depression: A STAR*D Report. CNS Spectrums, 2009, 14, 487-498.	1.2	10
543	Screening for postnatal depression in Chinese-speaking women using the Hong Kong translated version of the Edinburgh Postnatal Depression Scale. Asia-Pacific Psychiatry, 2013, 5, E64-E72.	2.2	10
544	Setting Measurement-Based Care in Motion: Practical Lessons in the Implementation and Integration of Measurement-Based Care in Psychiatry Clinical Practice. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 1621-1631.	2.2	10
545	Genomics-based identification of a potential causal role for acylcarnitine metabolism in depression. Journal of Affective Disorders, 2022, 307, 254-263.	4.1	10
546	Growth hormone response to baclofen: a comparison of 10-mg and 20-mg doses in healthy men. Psychiatry Research, 1996, 60, 41-47.	3.3	9
547	Strategies for Implementing Psychiatric Medication Algorithms in the Public Sector. Journal of Psychiatric Practice, 1999, 5, 32-36.	0.7	9
548	A Quality Improvement Process for Implementing the Texas Algorithm for Schizophrenia in Ohio. Psychiatric Services, 2003, 54, 1646-1649.	2.0	9
549	Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder. Australian and New Zealand Journal of Psychiatry, 2009, 43, 956-967.	2.3	9
550	Performance of depression rating scales in patients with chronic kidney disease: an item response theory-based analysis. General Hospital Psychiatry, 2016, 42, 60-66.	2.4	9
551	Prognostic Utility of a Self-Reported Depression Questionnaire versus Clinician-Based Assessment on Renal Outcomes. American Journal of Nephrology, 2016, 44, 234-244.	3.1	9
552	Toward a very brief self‐report to assess the core symptoms of depression (VQIDS‐SR$_5$). Acta Psychiatrica Scandinavica, 2017, 135, 548-553.	4.5	9
553	At the Research Front: Cognitive Therapy for Depression. Australian and New Zealand Journal of Psychiatry, 1979, 13, 13-16.	2.3	8
554	Depression spectrum disease with and without depression in first-degree relatives. Journal of Affective Disorders, 1995, 35, 131-138.	4.1	8
555	Desipramine Versus Phenelzine in Recurrent Unipolar Depression. Journal of Clinical Psychopharmacology, 1997, 17, 78-83.	1.4	8
556	<p>The Long and Winding Road of Vagus Nerve Stimulation: Challenges in Developing an Intervention for Difficult-to-Treat Mood Disorders</p>. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 3081-3093.	2.2	8
557	Natural Language Processing-Based Quantication of the Mental State of Psychiatric Patients. Computational Psychiatry, 2020, 4, 76.	2.0	8
558	Serum concentrations of deoxycorticosterone in women during the luteal phase of the ovarian cycle are not suppressed by dexamethasone treatment. The Journal of Steroid Biochemistry, 1983, 19, 1313-1317.	1.1	7

#	Article	IF	Citations
559	Naturalistic study of the early psychiatric use of citalopram in the United States. Depression and Anxiety, 2002, 16, 121-127.	4.1	7
560	Pretreatment Correlates of the Therapeutic Alliance in the Chronically Depressed. Journal of Contemporary Psychotherapy, 2002, 32, 281-290.	1.2	7
561	Methods of testing feasibility for sequenced treatment alternatives to relieve depression (STAR*D). Journal of Psychiatric Research, 2004, 38, 241-248.	3.1	7
562	Development of a computerized assessment of clinician adherence to a treatment guideline for patients with bipolar disorder. Journal of Psychiatric Research, 2004, 38, 285-294.	3.1	7
563	Developing the evidence for evidence-based practice. Cmaj, 2008, 178, 1313-1315.	2.0	7
564	Data-driven longitudinal modeling and prediction of symptom dynamics in major depressive disorder: Integrating factor graphs and learning methods. , 2017, , .		7
565	Screening for panic-related anxiety in emergency department patients with cardiopulmonary complaints: A comparison of two self-report instruments. Psychiatry Research, 2018, 263, 7-14.	3.3	7
566	Clinical Implications of the STAR*D Trial. Handbook of Experimental Pharmacology, 2018, 250, 51-99.	1.8	7
567	Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials. International Journal of Neuropsychopharmacology, 2019, 22, 339-348.	2.1	7
568	The Concise Health Risk Tracking Selfâ€Report (CHRTâ€SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. Depression and Anxiety, 2019, 36, 313-320.	4.1	7
569	Using the NIH Research, Condition and Disease Categorization Database for research advocacy: Schizophrenia research at NIMH as an example. PLoS ONE, 2020, 15, e0241062.	2.5	7
570	Depressive disorders: treatment patterns and costs of treatment in the private sector of the United States. Social Psychiatry and Psychiatric Epidemiology, 1995, 30, 224-230.	3.1	7
571	Practice guidelines in mental health and addiction services: contributions from the American College of Mental Health Administration. Administration and Policy in Mental Health and Mental Health Services Research, 2002, 30, 21-33.	2.1	6
572	Clinician ratings vs. global ratings of symptom severity: a comparison of symptom measures in the bipolar disorder module, phase II, Texas Medication Algorithm Project. Psychiatry Research, 2003, 117, 167-175.	3.3	6
573	The Implementation of Cognitive Therapy in STAR*D. Cognitive Therapy and Research, 2004, 28, 819-833.	1.9	6
574	Quality improvement methods as applied to a multicenter effectiveness trialâ€"STAR*D. Contemporary Clinical Trials, 2005, 26, 95-112.	1.8	6
575	Psychotherapy of the affective psychoses. American Journal of Psychoanalysis, 1980, 40, 99-123.	0.4	5
576	Polysomnogram in major depressive and obsessiveâ€compulsive disorders: A preliminary study. Depression, 1994, 2, 297-302.	0.6	5

#	Article	IF	Citations
577	Validation of the Inventory of Depressive Symptomatology (IDS) in Cocaine Dependent Inmates. Journal of Offender Rehabilitation, 2001, 32, 15-30.	0.8	5
578	Dr. Trivedi and Colleagues Reply. American Journal of Psychiatry, 2006, 163, 1293-1294.	7.2	5
579	Insured and Non-insured Depressed Outpatients: How Do They Compare?. Annals of Clinical Psychiatry, 2007, 19, 73-82.	0.6	5
580	The role of efficacy and effectiveness trials. World Psychiatry, 2009, 8, 34-35.	10.4	5
581	Tools to facilitate the teaching and enhance the practice of psychopharmacology. Asian Journal of Psychiatry, 2016, 19, 21-22.	2.0	5
582	Impact of childhood maltreatment on outcomes of antidepressant medication in chronic and/or recurrent depression. Journal of Affective Disorders, 2021, 291, 39-45.	4.1	5
583	Arecoline reverses dexamethasone suppression of cortisol in normal males: A pilot study. Biological Psychiatry, 1995, 37, 811-816.	1.3	4
584	Relapse of Depressive Symptoms After Discontinuing Sertraline. JAMA - Journal of the American Medical Association, 1999, 282, 323.	7.4	4
585	A Review of Vagus Nerve Stimulation for Treatment-Resistant Depression. Epilepsy and Behavior, 2001, 2, S6-S10.	1.7	4
586	Differential Responses to Psychotherapy Versus Pharmacotherapy in Patients With Chronic Forms of Major Depression and Childhood Trauma. Focus (American Psychiatric Publishing), 2005, 3, 131-135.	0.8	4
587	Effects of heart disease on depression treatment: results from the COMED study. General Hospital Psychiatry, 2012, 34, 24-34.	2.4	4
588	Variable and threshold selection to control predictive accuracy in logistic regression. Journal of the Royal Statistical Society Series C: Applied Statistics, 2014, 63, 657-672.	1.0	4
589	The need for paediatric registries to assess long-term brain effects of psychotropic medications: The case of bipolar disorder. European Neuropsychopharmacology, 2018, 28, 1181-1184.	0.7	4
590	The Effectiveness of Antidepressant Monotherapy in a Naturalistic Outpatient Setting. primary care companion for CNS disorders, The, 2012, 14, .	0.6	4
591	Anterior cingulate cortex in individuals with depressive symptoms: A structural MRI study. Psychiatry Research - Neuroimaging, 2022, 319, 111420.	1.8	4
592	Clinical Diagnosis of Mood Disorders. Clinical Chemistry, 1988, 34, 2370-2370.	3.2	3
593	Point. Academic Psychiatry, 1996, 20, 238-240.	0.9	3
594	Genetic Markers of Suicidal Ideation Emerging During Citalopram Treatment of Major Depression. Focus (American Psychiatric Publishing), 2008, 6, 69-79.	0.8	3

#	Article	IF	Citations
595	Engaging Depressed Patients: An Essential Step in Optimizing Care. American Journal of Psychiatry, 2017, 174, 506-507.	7.2	3
596	Targeting treatments for depression: what can our patients tell us?. Epidemiology and Psychiatric Sciences, 2017, 26, 37-39.	3.9	3
597	Accurately identifying patients who are excellent candidates or unsuitable for a medication: a novel approach. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 3001-3010.	2.2	3
598	The Adolescent Resilience Questionnaire: Validation of a Shortened Version in U.S. Youths. Frontiers in Psychology, 2020, 11, 606373.	2.1	3
599	Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder. Journal of Affective Disorders, 2021, 282, 602-610.	4.1	3
600	Recommendations for Depression Publications. British Journal of Psychiatry, 1983, 143, 638-639.	2.8	3
601	Making Therapy Widely Available: Clinical Research Triumph or Existential Catastrophe?. American Journal of Psychiatry, 2022, 179, 79-82.	7.2	3
602	Voice response system to measure healthcare costs: a STAR*D report. American Journal of Managed Care, 2009, 15, 153-62.	1.1	3
603	Psychometric and Clinical Evaluation of the Clinician (VQIDS-C5) and Self-Report (VQIDS-SR5) Versions of the Very Quick Inventory of Depressive Symptoms. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 289-302.	2.2	3
604	Recommendations for depression publications. Psychoneuroendocrinology, 1983, 8, 355-357.	2.7	2
605	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. Focus (American Psychiatric Publishing), 2008, 6, 104-119.	0.8	2
606	Dr. Rush Replies. American Journal of Psychiatry, 2008, 165, 133-134.	7.2	2
607	Anticipated Benefits of Care (ABC): psychometrics and predictive value in psychiatric disorders. Psychological Medicine, 2010, 40, 955-965.	4.5	2
608	Response to Blier Letter. American Journal of Psychiatry, 2012, 169, 95-96.	7.2	2
609	Addressing the unmet needs of current antidepressants: does neuroscience help or hinder clinical psychopharmacology research?. Expert Opinion on Pharmacotherapy, 2017, 18, 1417-1420.	1.8	2
610	Psychometric Evaluation of the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire in a General Youth Population. Child Psychiatry and Human Development, 2021, , 1.	1.9	2
611	Improving Depression Outcome by Patient-Centered Medical Management. Focus (American Psychiatric) Tj ETQq1 1 0.784314 rgBT /C	0.8	2
612	Do Depressed Patients With Diabetes Experience More Side Effects When Treated With Citalopram Than Their Counterparts Without Diabetes?. Primary Care Companion To the Journal of Clinical Psychiatry, 2009, 11, 186-196.	0.6	2

#	Article	IF	Citations
613	Placebo Responsiveness Does Not Imply that Placebo Is a Sufficient Treatment. Neuropsychopharmacology, 1994, 10, 281-283.	5.4	1
614	Fluoxetine Versus Placebo in Preventing Relapse of Major Depression in Children and Adolescents. Focus (American Psychiatric Publishing), 2008, 6, 348-357.	0.8	1
615	Cognitive Therapy Augmentation versus CT Switch Treatment: A STAR*D Report. International Journal of Cognitive Therapy, 2009, 2, 66-87.	2.2	1
616	Release bias in accessing medical records in clinical trials: a STAR*D report. International Journal of Methods in Psychiatric Research, 2009, 18, 147-158.	2.1	1
617	Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. Focus (American Psychiatric Publishing), 2012, 10, 492-505.	0.8	1
618	What Did STARâœ«D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression. Focus (American Psychiatric Publishing), 2012, 10, 510-517.	0.8	1
619	Can the digital revolution improve care for mood disorders patients?. Journal of Affective Disorders, 2021, 282, 1193-1194.	4.1	1
620	Medical Test Development and Implementation: A Multistep Journey. Journal of Clinical Psychiatry, 2015, 76, e220-e221.	2.2	1
621	Dr. Scheffer and Colleagues Reply. American Journal of Psychiatry, 2005, 162, 2197-a-2198.	7.2	0
622	Experimental therapeutics and biological psychiatry. Biological Psychiatry, 2005, 57, 695.	1.3	0
623	Maintaining a Steady Course. Biological Psychiatry, 2005, 58, 433-434.	1.3	0
624	Special Issue on Therapeutics. Biological Psychiatry, 2006, 59, 989.	1.3	0
625	Antecedentes familiares de suicidio consumado y caracterÃsticas del trastorno depresivo mayor: estudio STAR*D (sequenced treatment alternatives to relieve depression). Psiquiatria Biologica, 2008, 15, 195-201.	0.1	0
626	Reply to El-Mallakh et al. Letter. American Journal of Psychiatry, 2010, 167, 996-997.	7.2	0
627	Ketamine for Treatment-Resistant Depression: Ready or Not for Clinical Use?. Focus (American) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.8	0
628	2017 in Review. American Journal of Psychiatry, 2017, 174, 1140-1143.	7.2	0
629	2018 in Review. American Journal of Psychiatry, 2018, 175, 1163-1166.	7.2	0
630	Blue Dreams: The Science and the Story of the Drugs That Changed Our Mindsby Lauren Slater. New York, Little, Brown, 2018, 416 pp., $28.00 (hardcover).. American Journal of Psychiatry, 2018, 175, 686-687.	7.2	0

#	Article	IF	Citations
631	Biomarkers: Where Are We Going?. Focus (American Psychiatric Publishing), 2018, 16, 123-123.	0.8	0
632	Reply to Self-Medication, Bipolar Disorders, and Stimulant Dependence. Journal of Clinical Psychiatry, 2009, 70, 936-937.	2.2	0
633	Do depressed patients with diabetes experience more side effects when treated with CitalopramThan their counterparts without diabetes? a STAR*D study. Primary Care Companion To the Journal of Clinical Psychiatry, 2009, 11, 186-96.	0.6	0
634	Title is missing!. , 2020, 15, e0241062.		0
635	Title is missing!. , 2020, 15, e0241062.		0
636	Title is missing!. , 2020, 15, e0241062.		0
637	Title is missing!. , 2020, 15, e0241062.		0
638	Title is missing!. , 2020, 15, e0241062.		0
639	Title is missing!. , 2020, 15, e0241062.		0
640	Title is missing!. , 2020, 15, e0241062.		0
641	Title is missing!. , 2020, 15, e0241062.		0